Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response...

Area of Science:

• Pharmacology
• Immunology
• Oncology

Background:

• Nivolumab, a monoclonal antibody, targets the PD-1 pathway, showing efficacy in various cancers.
• Time-varying clearance of nivolumab was observed, linked to disease status changes.
• This interaction can bias exposure-response (E-R) relationship estimates.

Purpose of the Study:

• To develop and verify a methodology for assessing the causal effect of drug exposure on clinical response.
• To address the bias in E-R relationship estimation due to time-varying clearance.
• To compare E-R analyses using early versus steady-state pharmacokinetic metrics.

Main Methods:

• Simulations were conducted to develop a novel methodology for causal E-R analysis.
• Data from nivolumab clinical trials were used for methodology verification.
• Pharmacokinetic (PK) metrics from the first dose were compared with steady-state PK metrics.

Main Results:

• A novel methodology was proposed and verified for assessing causal drug exposure-response relationships.
• E-R analyses using PK metrics from the first dose showed greater consistency with the true relationship.
• Steady-state PK metrics led to biased and steep E-R estimates.

Conclusions:

• Early pharmacokinetic metrics provide a more accurate assessment of nivolumab's exposure-response relationship.
• The proposed methodology helps to overcome bias in E-R analyses caused by time-varying drug clearance.
• Accurate E-R analysis is crucial for optimizing cancer immunotherapy efficacy.